At-home collection, one-day fecal immunochemical test that meets American Cancer Society guidelines and HEDIS quality measures for lower gastrointestinal bleeding screening programs A number of ...

Commercial FITs can match NG-MSDT diagnostic results for CRC by lowering the positivity threshold, enhancing sensitivity while maintaining specificity. FITs are accessible, noninvasive CRC screening ...

Colorectal cancer continues to be one of the leading causes of cancer-related deaths worldwide. However, recent advancements in medical screening have brought new hope in the fight against this deadly ...

A next-generation multitarget stool DNA test, including assessments of DNA molecular markers and hemoglobin level, was developed to improve the performance of colorectal cancer screening, primarily ...

Multitarget stool-based tests are showing promise for colorectal cancer (CRC) screening in average-risk individuals and could edge out the current standard fecal immunochemical test (FIT). These new ...

Noninvasive surveillance with multitarget stool DNA testing or fecal immunochemical testing (FIT) could potentially match colonoscopy for reducing long-term ...